Webinar
Development of an assay and screening platform to study molecular glue degraders
Discover how targeting RNA-binding motif protein 39 (RBM39) is unlocking new possibilities in cancer treatment. Learn from experts at Abbvie and Fraunhofer ITMP in the use of molecular glue degraders and advanced HTRF technology to quantify RBM39 degradation in neuroblastoma cancer cells.
For research use only. Not for use in diagnostic procedures.
To view the full content please answer a few questions